Susan Lovick

Selumetinib in Combination With Dacarbazine in Patients With Metastatic Uveal Melanoma: A Phase III, Multicenter, Randomized Trial (SUMIT)

Richard D. Carvajal, Sophie Piperno‐Neumann, Ellen Kapiteijn et al. · Journal of Clinical Oncology · 2018 · 275 citations · Full text

Medicine, Oncology, Pharmacology +15

SELECT-2: a phase II, double-blind, randomized, placebo-controlled study to assess the efficacy of selumetinib plus docetaxel as a second-line treatment of patients with advanced or metastatic non-small-cell lung cancer

J.C. Soria, András Fülöp, Carlos Dias Maciel et al. · Annals of Oncology · 2017 · 31 citations · Full text

Medicine, Oncology, Pharmacology +16

Effect of Pretreatment With Atenolol and Nifedipine on ZD6126-Induced Cardiac Toxicity in Rats

Sarah Gould, F. Russell Westwood, Jon Curwen et al. · JNCI Journal of the National Cancer Institute · 2007 · 28 citations · Full text

Medicine, Cardiology, Pharmacology +15

Pharmacokinetics and pharmacogenetics of the MEK1/2 inhibitor, selumetinib, in Asian and Western healthy subjects: a pooled analysis

Angela W. Dymond, Cathy E. Elks, Paul Martin et al. · European Journal of Clinical Pharmacology · 2017 · 18 citations · Full text

Veterinary Medicine, Pharmacokinetics, Pharmacology +17

OA05.06 Datopotamab Deruxtecan (Dato-DXd) + Durvalumab ± Carboplatin in Advanced/mNSCLC: Initial Results from Phase 1b TROPION-Lung04

K. Papadopoulos, Débora S. Bruno, Satoru Kitazono et al. · Journal of Thoracic Oncology · 2023 · 13 citations · Full text

Medicine, Oncology, Pharmacology +11